Q/Which women should we screen for gestational diabetes mellitus?

EVIDENCE-BASED ANSWER

A/It’s unclear which women we should screen. No randomized controlled trials (RCTs) demonstrate that either universal screening or risk factor screening for gestational diabetes mellitus (GDM) prevents maternal and fetal adverse outcomes.

That said, the common practice of universal screening is more sensitive than screening based on risk factors (strength of recommendation [SOR]: B, 1 randomized trial and 3 retrospective cohort studies without patient-oriented outcomes). Historic risk factors are poor predictors of GDM in a current pregnancy (SOR: C, 1 retrospective cohort study without patient-oriented outcomes).

Evidence summary

No RCTs have evaluated the risks, benefits, and clinical outcomes of screening for GDM. A review of universal screening compared with risk factor screening included 2 retrospective studies, 1 observational cohort study, and 1 nonconcurrent cohort study.1-4

Risk factor screening misses women with GDM

All 4 studies clearly show that risk factor screening would miss patients with GDM.1-4 Two studies found that the detection rate of GDM increases when universal screening is performed.1,4

One observational study in a multi-ethnic cohort concluded that risk factor screening missed 30% of patients with GDM.1,4 Two studies found that the detection rate of GDM increased the detection rate from 8.3% to 12.6% (P=.001) compared with risk factor screening.1 Similarly, a retrospective study of 147 pregnant women with GDM found that risk factor screening would have missed 23%.2

Universal screening diagnoses GDM earlier than risk factor screening

One prospective randomized study that compared universal screening (using a 50-g 1-hour glucose challenge test) in 1853 women with risk factor screening in 1299 women demonstrated that nearly half of those with GDM had no historical risk factors and would have been missed by risk factor screening in a low-prevalence, mostly Caucasian sample. The prevalence was 2.7% in the universal screening group vs 1.45% in the risk factor screening group (P<.03). Universal screening diagnosed GDM earlier than risk factor screening (mean gestation 30 ± 2.6 weeks vs 33 ± 3.7 weeks; P<.05).3

Need for insulin is similar, with and without GDM risk factors

A retrospective cohort study demonstrated that risk factor screening misses 43% of women with GDM. The study also showed that women with GDM who had identifiable risk factors and women without identifiable risk factors were equally likely to require insulin to control their GDM. Adverse birth outcomes such as macrosomia and shoulder dystocia or cesarean section were similar in patients with and without risk factors for GDM.4

Macrosomia and primary C-section increase along with glucose intolerance

The prospective cohort Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study

Shahla Namak, MD; Richard W. Lord Jr, MD, MA; Adam J. Zolotor, MD, MPH
Wake Forest University School of Medicine, Winston Salem, NC (Drs. Namak and Lord); University of North Carolina at Chapel Hill (Dr. Zolotor)

Rochelle Kramer, MLS, AHIP
Carpenter Library, Wake Forest University School of Medicine, Winston-Salem, NC
of 23,316 women at 15 centers in 9 countries used the 2-hour 75-g oral glucose tolerance test at 24 to 32 weeks’ gestation to clarify the risks of adverse outcomes associated with varying degrees of maternal glucose intolerance. The study found a linear increase in the risk of macrosomia and primary cesarean section as glucose intolerance levels increased from normal to the gestational diabetes range.5

**Recommendations**
The US Preventive Services Task Force states that evidence is insufficient to advise for or against routine screening for GDM.6

The American College of Obstetricians and Gynecologists considers universal glucose challenge screening for GDM to be the most sensitive approach, but notes that some pregnant women at low risk may be less likely to benefit from testing.7

The Cochrane review protocol states that universally accepted screening is controversial because of a lack of clearly defined, universally accepted screening criteria and uncertainty about the severity of glucose intolerance at which treatment is beneficial.8

---

**References**